Trials / Completed
CompletedNCT05765604
Phase I Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) (WSK-V102)
A Randomized, Parallel Controlled, Double-blind, Single-center Phase I Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell)(WSK-V102) in People Aged 18 Years or Older
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- WestVac Biopharma Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Accepted
Summary
Subjects aged 18 and above who have been completed primary or booster vaccination of COVID-19 inactivated vaccines for 3 months or more, to conduct a randomized, parallel controlled, double-blind, single-center phase I clinical trial of Recombinant variant COVID-19 vaccine (Sf9 cell)(WSK-V102) to evaluate the safety, tolerance and immunogenicity of this vaccine in the study population.
Detailed description
Low and high doses of study vaccine were compared with control groups to evaluate the safety and immunogenicity of the study vaccine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Recombinant COVID-19 variant vaccine(Sf9 cell) | IM |
| BIOLOGICAL | Recombinant COVID-19 vaccine(CHO cell) | IM |
Timeline
- Start date
- 2023-03-14
- Primary completion
- 2023-07-30
- Completion
- 2024-03-30
- First posted
- 2023-03-13
- Last updated
- 2025-03-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05765604. Inclusion in this directory is not an endorsement.